Clinical Trials Logo

Clinical Trial Summary

This is an investigational, single arm study.

Clinical Trial Description

Pembrolizumab is FDA approved and commercially available for treatment of many types of cancers. It is considered investigational to use chemotherapy combined with pembrolizumab to treat thymoma or Thymic carcinoma. Subjects will be evaluated for eligibility during a 28-day screening period. Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab. Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Up to 40 participants will be enrolled in this study. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04554524
Study type Interventional
Source Tang-Du Hospital
Contact Yongan Zhou
Phone 86-13700287519
Status Recruiting
Phase Phase 4
Start date August 27, 2020
Completion date July 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT00003283 - Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Phase 2
Completed NCT00372840 - Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer N/A
Completed NCT00024076 - Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Phase 2
Completed NCT02636556 - Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors N/A
Completed NCT02049047 - Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Phase 2
Recruiting NCT02633514 - Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Phase 3
Active, not recruiting NCT03663764 - Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor Phase 2
Recruiting NCT06301945 - Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors